Xinhe Bio Recognized as 'Ernst & Young Fudan 2021 Most Promising Seed Enterprise' Amid RNA Therapeutics Breakthrough

On September 23, 2021, the "EY-Fudan China Most Promising Enterprises 2021 Awards Ceremony and High-Growth Enterprises Symposium" was held in Shanghai, unveiling the 25 most promising enterprises across seven major sectors: advanced manufacturing, strategic emerging industries, future industries, modern services, emerging services, infrastructure, and the digital economy. NeoCura Bio-Medical Technology Co., Ltd. stood out from numerous applicants and was honored as an "EY-Fudan 2021 Most Promising Seed Enterprise"!

Dr. Wang Yi, Founder & CEO of NeoCura, stated in his acceptance speech: “We are deeply grateful to the judging committee for awarding this honor to NeoCura. This recognition serves as both an affirmation of our efforts and a driving force for our continued progress. Since its inception, NeoCura has been dedicated to the research of innovative RNA therapeutics. We aim to leverage AI and bioinformatics technologies to advance the R&D of novel RNA-based drugs, enabling more cancer patients to benefit from this emerging treatment modality, thereby improving their quality of life, extending survival, and bringing a new dawn of hope to oncology patients.”

In 2021, as China's economic and social development entered the 14th Five-Year Plan period, numerous outstanding Chinese enterprises brought new perspectives to the market along this highly challenging path. The "EY-Fudan Most Potential Enterprise 2021" selection campaign spanned five months, with the jury focusing on evaluating enterprises' comprehensive strengths based on criteria such as "strong future growth potential and sustainable development," "development in China and internationally," and "distinct competitive advantages." Ultimately, 25 enterprises with exceptional overall capabilities were selected, aiming to identify future industry leaders who buck the trend, disrupt and transform traditional technological fields, and further tap into market potential.

In this evaluation, next-generation artificial intelligence and gene & biotechnology were designated as two strategic directions for China's future industries. NeoCura, as an AI-driven RNA therapeutics R&D company, has emerged as a standout industry leader. Following the center-stage emergence of the COVID-19 mRNA vaccine, mRNA technology has achieved breakthrough advancements. With its dedicated focus on RNA therapeutics R&D, NeoCura has also entered a fast track of growth, becoming a focal point for both the industry and capital markets.
 
NeoCura is dedicated to establishing an internationally leading innovative RNA therapeutics platform. The company has built a multi-omics big data collection platform and an integrated multi-omics database, leveraging AI and bioinformatics technologies for in-depth drug target discovery and fully automated drug design to drive the R&D of innovative RNA therapeutics. NeoCura has already expanded its pipeline across multiple therapeutic areas, including tumor neoantigen vaccines and tumor microenvironment immunomodulatory agents. Looking ahead, NeoCura will accelerate IND applications for its in-development RNA drug pipeline, further accumulate real-world data on tumor neoantigens, and broaden the exploration of clinical protocols for cancer immunotherapy. NeoCura aims to contribute to technological breakthroughs across the global RNA pharmaceutical industry chain and advance the clinical application of cancer immunotherapy worldwide.

Original link:EY-Fudan China's Most Promising Enterprise 2021 Awards Announced Today! 25 Emerging Enterprises Shortlisted